Holen Sie sich die Stockscreener-App
6.8366
0.15%
-0.0334
Schlusskurs vom Vortag:
$6.87
Offen:
$6.95
24-Stunden-Volumen:
19,255
Relative Volume:
0.07
Marktkapitalisierung:
$253.10M
Einnahmen:
$128.45M
Nettoeinkommen (Verlust:
$6.54M
KGV:
136.73
EPS:
0.05
Netto-Cashflow:
$-8.79M
1W Leistung:
-2.00%
1M Leistung:
-5.90%
6M Leistung:
-8.17%
1J Leistung:
+18.07%
1-Tages-Spanne:
$6.765
$6.95
1-Wochen-Bereich:
$6.455
$7.6174
52-Wochen-Spanne:
$3.6793
$7.99
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Firmenname
Lifecore Biomedical Inc
Sektor
Telefon
(952) 368-4300
Adresse
3515 LYMAN BOULEVARD, CHASKA
Vergleichen Sie LFCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
6.835 | 259.18M | 128.45M | 6.54M | -8.79M | 0.05 |
|
HLN
Haleon Plc Adr
|
11.13 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
171.34 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.86 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.95 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.27 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Eingeleitet | William Blair | Outperform |
| 2024-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | Herabstufung | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Aktie (LFCR) Neueste Nachrichten
Deutsche Bank AG Reduces Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Contrasting Lifecore Biomedical (NASDAQ:LFCR) & Liquidia (NASDAQ:LQDA) - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by BNP Paribas Financial Markets - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago - Yahoo Finance
How the (LFCR) price action is used to our Advantage - news.stocktradersdaily.com
Lifecore appoints new chief commercial officer to drive growth By Investing.com - Investing.com South Africa
Lifecore Biomedical Appoints CCO - Contract Pharma
Lifecore Biomedical Names Mark Dafonseca Chief Commercial Officer - marketscreener.com
LFCR Appoints New Chief Commercial Officer | LFCR Stock News - GuruFocus
Lifecore appoints new chief commercial officer to drive growth - Investing.com
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer - GlobeNewswire
Lifecore Biomedical Taps 30-Year Pharma Veteran as CCO to Accelerate CDMO Market Expansion - Stock Titan
Northern Trust Corp Purchases 28,019 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Analysts Set Expectations for LFCR Q4 Earnings - Defense World
William Blair Begins Coverage on Lifecore Biomedical (NASDAQ:LFCR) - Defense World
What Makes Lifecore Biomedical (LFCR) a Beneficiary of the Trade Policies? - Insider Monkey
Lifecore Biomedical (LFCR) Receives 'Outperform' Rating from Wil - GuruFocus
Lifecore stock gains on Outperform rating by William Blair - Investing.com Canada
William Blair Initiates Coverage on Lifecore Biomedical With Outperform Rating - marketscreener.com
Greenhaven Road Capital Main Fund Q1 2025 Top 5 Holdings - Seeking Alpha
Barclays PLC Buys 4,028 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Wells Fargo & Company MN Has $99,000 Stock Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) hedge funds shareholders had a great week as one-year returns increased after a 11% gain last week - Yahoo Finance
A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Raises Stock Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
When the Price of (LFCR) Talks, People Listen - news.stocktradersdaily.com
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference - The Manila Times
Quality Management Expert from Lifecore to Chair Strategic Discussion at Major CDMO Conference - Stock Titan
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lifecore Appoints Top Legal Executive: Stock Price Targets Set at 5x Current Value - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Lifecore Biomedical Taps Thomas Salus as Chief Legal & Administration Officer - Contract Pharma
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer - GlobeNewswire
Lifecore Strengthens Leadership: Former Viatris Legal Chief Joins to Drive Strategic Growth - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Prudential Financial Inc. Makes New $95,000 Investment in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical secures stockholder nod for share issuance - Investing.com Australia
Lifecore Biomedical secures stockholder nod for share issuance By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out - markets.businessinsider.com
Finanzdaten der Lifecore Biomedical Inc-Aktie (LFCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.28%
2.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):